Indigenous-led cancer control The Lancet Oncology +... + +

https://www.thelancet.com/journals/lanonc/issue/vol27no8/PIIS1470-2045(26)X2007-1 Indigenous-led cancer control The Lancet Oncology Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research Babita Kataria, DMa ∙ Asima Mukhopadhyay, MDb ∙ Ana Oaknin, MDc ∙ Dearbhaile M O'Donnell, MDd ∙ David S P Tan, MDe ∙ Prof David Cibula, MDf ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00215-9/abstract?dgcid=raven_jbs_etoc_feature_lanonc Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial Prof Herui Yao, MDa,* ∙ Prof Qingyuan Zhang, MDb,* ∙ Prof Huiping Li, MDc,* ∙ Prof Yongmei Yin, MD*,d ∙ Prof Shusen Wang, MD*,e ∙ Prof Quchang Ouyang, MDf,* ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00193-2/abstract?dgcid=raven_jbs_etoc_feature_lanonc